13 Jun Potential Side Effects of Immunotherapy in Head and Neck Cancer
Dan Zandberg, MD Introduction Currently, two immunotherapy medications, Nivolumab (Opdivo) and Pembrolizumab (Keytruda) are approved in the USA for recurrent and or metastatic squamous cell carcinoma of head and neck (HNSCC) after...